Skip to main content
profile image
Selected Works of Philip Mease, MD
Presentation
Secukinumab leads to 2-year sustained minimal disease activity in patients with active psoriatic arthritis: Results of the Phase-3 FUTURE-2 Study. 19th Asia Pacific League of Associations for Rheumatology Congress (APLAR 2017), Dubai, U.A.E., Oct 2017.
19th Asia Pacific League of Associations for Rheumatology Congress (APLAR 2017) (2017)
  • P Nash
  • Philip Mease, Providence St. Joseph Health
  • et.al.
Link
Disciplines
Publication Date
October, 2017
Citation Information
P Nash, Philip Mease and et.al.. "Secukinumab leads to 2-year sustained minimal disease activity in patients with active psoriatic arthritis: Results of the Phase-3 FUTURE-2 Study. 19th Asia Pacific League of Associations for Rheumatology Congress (APLAR 2017), Dubai, U.A.E., Oct 2017." 19th Asia Pacific League of Associations for Rheumatology Congress (APLAR 2017) (2017)
Available at: http://works.bepress.com/philip-mease/184/